Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Traws Pharma ( (TRAW) ) has provided an update.
On March 28, 2025, Traws Pharma announced the retirement of CEO Werner Cautreels, effective March 31, 2025, with Iain D. Dukes stepping in as Interim CEO. Dr. Cautreels will remain on the Board and transition to a consulting role, while Dr. Dukes, with extensive leadership experience, will continue as Chairman. The company is advancing its antiviral programs for bird flu and COVID-19, with an investor update scheduled for March 31, 2025.
More about Traws Pharma
Traws Pharma is a clinical-stage biopharmaceutical company focused on developing novel therapies for respiratory viral diseases. Their investigational antiviral agents target difficult-to-treat or resistant virus strains, with product candidates including tivoxavir marboxil for bird flu and seasonal influenza, and ratutrelvir for COVID-19.
YTD Price Performance: -70.36%
Average Trading Volume: 127,977
Technical Sentiment Signal: Buy
Current Market Cap: $12.94M
Learn more about TRAW stock on TipRanks’ Stock Analysis page.